11th week of 2016 patent applcation highlights part 9 |
Patent application number | Title | Published |
20160074379 | Antimicrobial Compounds - This disclosure relates to compositions including certain compounds identified by a quantitative, high throughput assay to be effective in inhibiting the ability of a bacterium to kill a host organism, as well as methods for using these compounds for treating bacterial infections. | 2016-03-17 |
20160074380 | Treatment Of Neurodegenerative Diseases With Combination Of Laquinimod And Fingolimod - This invention provides a method of treating a subject afflicted with a neurodegenerative disease comprising periodic administration of an amount of laquinimod and an amount of fingolimod, wherein the amounts when taken together are effective to treat the subject. Also provided are packages and pharmaceutical compositions comprising laquinimod and fingolimod for treating a subject afflicted with a neurodegenerative disease. Also provided is a pharmaceutical composition comprising laquinimod for use as an add-on therapy or in combination with fingolimod, and a pharmaceutical composition comprising fingolimod for use as an add-on therapy or in combination with laquinimod, for treating said subject. | 2016-03-17 |
20160074381 | MODULATORS OF CELLULAR ADHESION - The present invention provides compounds having formula (I): | 2016-03-17 |
20160074382 | Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan - Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin. | 2016-03-17 |
20160074383 | ORALLY ADMINISTRABLE COMPOSITIONS AND METHODS OF DETERRING ABUSE BY INTRANASAL ADMINISTRATION - Orally administrable pharmaceutical compositions and methods of administration are provided. The pharmaceutical compositions provide abuse deterrent properties. | 2016-03-17 |
20160074384 | EXTENDING AND MAINTAINING MICROPORE VIABILITY OF MICRONEEDLE TREATED SKIN WITH LIPID BIOSYNTHESIS INHIBITORS FOR SUSTAINED DRUG DELIVERY - Microneedles and their use as a physical skin permeation enhancement technique facilitate drug delivery across the skin in therapeutically relevant concentrations. Micropores created in the skin by MNs reseal because of normal healing processes of the skin, thus limiting the duration of the drug delivery window. Pore lifetime enhancement strategies can increase effectiveness of MNs as a drug delivery mechanism by prolonging the delivery window. Fluvastatin (FLU) was used to enhance pore lifetime by inhibiting the synthesis of cholesterol, a major component of the stratum corneum lipids. The skin recovered within a 30-45-min time period following the removal of occlusion, and there was no significant irritation observed due to the treatment compared to the control sites. Thus, it can be concluded that localized skin treatment with FLU can be used to extend micropore lifetime and deliver drugs for up to 7 days across MN-treated skin. | 2016-03-17 |
20160074388 | ABUSE-PROOFED DOSAGE FORM - The present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof. | 2016-03-17 |
20160074389 | CAVEOLIN-1 RELATED METHODS FOR TREATING GLIOBLASTOMA WITH TEMOZOLOMIDE - This invention provides a method for treating a subject afflicted with glioblastoma multiforme comprising administering a therapeutically effective regimen of temoxolomide to be glioblastoma multiforme-afflicted subject, wherein the subject's glioblastoma multiforme cells are known to be caveolin-1-positive. This invention also provides a method for determining whether a subject afflicted with glioblastoma multiforme is likely to progress therapeutically in response to a therapeutically effective regimen of temoxolomide comprising determining whether the subject's glioblastoma multiforme cells are caveolin-1-positive, whereby if the subject's glioblastoma multiforme cells are caveolin-1-positive, the subject is likely to progress therapeutically in response to a therapeutically effective regimen of temozolomide. | 2016-03-17 |
20160074390 | HUMAN DOSING OF PHOSPHATASE INHIBITOR - The present invention provides a method of inhibiting protein phosphatase 2A (PP2A) in a human subject in need thereof comprising administering to the subject an amount of from 0.1 mg/m | 2016-03-17 |
20160074391 | MEANS AND METHODS FOR TREATING CANCER - The present invention relates to a pharmaceutical composition comprising a compound of formula (I) | 2016-03-17 |
20160074392 | TREATMENT AND PROGNOSTIC MONITORING OF PROLIFERATION DISORDERS USING HEDGEHOG PATHWAY INHIBITORS - The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy. | 2016-03-17 |
20160074393 | TREATMENT AND PROGNOSTIC MONITORING OF PROLIFERATION DISORDERS USING HEDGEHOG PATHWAY INHIBITORS - The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy. | 2016-03-17 |
20160074394 | METHOD OF TREATMENT - The present invention relates to a method of treating T cell mediated inflammatory immune diseases or T cell mediated hypersensitivity diseases, which comprises administering to a human in need thereof an effective amount of a compound which inhibits EZH2 and/or EZH1, or a pharmaceutically acceptable salt thereof. | 2016-03-17 |
20160074395 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS - Substituted 5-(pyrazin-2-yl)-1H-pyrazolo[3, 4-b]pyridine, 5-(pyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridine and pyrazolo[3,4-b]pyridine derivatives according to formula I, II and VII, and methods for making same, which are inhibitors of constitutively activated Tyrosine Kinase-Like (TKL), CMGC protein kinases family members and can be useful in the treatment of Parkinson's disease, Alzheimer's disease, Down's Syndrome, Huntington's disease, other neurodegenerative and central nervous system disorders, cancer, metabolic disorders and inflammatory diseases. Also disclosed are pharmaceutical compositions including the compounds and methods of inhibiting wild type and/or mutated protein kinase activities of these families and the treatment of disorders associated therewith using compounds and pharmaceutical compositions including the compounds. | 2016-03-17 |
20160074396 | TADALAFIL FREE BASE-CONTAINING FILM DOSAGE FORM CONTAINING POLYETHYLENE GLYCOL-BASED POLYMER AND/OR VINYL PYRROLIDONE-BASED POLYMER AS DISPERSION STABILIZER - The present disclosure relates to a film formulation for oral administration, containing tadalafil free base and a method of preparing the same, and a film may be provided with maximized dispersion stability of tadalafil free base in the film by the addition of a dispersion stabilizing agent in small amounts without unique fragrance or favor that may appear when other dispersion stabilizing agents known in the art are used, and an extremely low likelihood that a reagglomeration phenomenon of tadalafil free base particles will occur, and an amount of bubbles generated may be significantly reduced during a production process. | 2016-03-17 |
20160074398 | PHARMACEUTICAL COMPOSITION CONTAINING CRYSTALLINE MACITENTAN - The present invention relates to an oral solid dosage form, in particular a tablet, comprising macitentan free base polymorphic form I. | 2016-03-17 |
20160074399 | Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor - The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same. Examples include hydrobromide and bis-besylate salts of N-(3-(2-(4-(4-acerylpiperazin-1-yl)-2-methoxyphenylamino)-5-(trifluoromethyl)pyrimidin-4-ylamino)phenyl)acrylamide). The salts and their polymorphs are evaluated for their properties such as stability, solubility, and pharmacokinetics. | 2016-03-17 |
20160074400 | WNT MODULATORS FOR THE PROTECTION, MITIGATION AND TREATMENT OF RADIATION INJURY - Provided are composition and methods for treating radiation-induced cell damage, and in particular aspects to methods for protecting, mitigating or otherwise treating radiation-induced induced depletion of tissue stem cells and injury to the supportive stem cell niche, and in even more particular aspects to methods for protecting, mitigating or otherwise treating radiation-induced gastrointestinal syndrome (RIGS), comprising sequential administration of a Wnt pathway activator/agonist (e.g., Rspo1 or a small molecule inducer thereof) that amplifies the surviving intestinal stem cell (ISC) pool post-radiation exposure, followed by a selective antagonist of the β-Catenin-CBP interaction (e.g., ICG-001 or other exemplary compounds disclosed herein) that accelerates differentiation of the stimulated (e.g., Rspo1-stimulated) ISC in crypt-villi axis, promoting villous regeneration and intestinal restitution, thereby mitigating RIGS. Adjunctive and combination therapy embodiments are encompassed. | 2016-03-17 |
20160074401 | COMPOSITIONS AND METHODS UTILIZING PHOSPHODIESTERASE INHIBITORS TO TREAT BLAST-INDUCED TINNITUS AND/OR HEARING LOSS - The present disclosure provides compositions and methods utilizing phosphodiesterase inhibitors to treat blast-induced tinnitus and/or hearing loss. The compositions include phosphodiesterase inhibitors such as sildenafil. | 2016-03-17 |
20160074402 | STABLE PHARMACEUTICAL COMPOSITION CONTAINING FOLATES - The administration of leucovorin as well as other active, reduced folates is useful as an antidote to drugs which act as folic acid antagonists and in combination chemotherapy with 5-FU. The most often used calcium salts of the folates have a low solubility in water and form almost insoluble degradation products. Therefore, aqueous solutions are unstable and precipitates result. Precipitates in injectable products present an unacceptable safety risk to patients. Stable high strength pharmaceutical aqueous compositions are formed containing calcium salts, magnesium or zinc salts of the reduced folates leucovorin, (6R,S)-tetrahydrofolic acid, (6S)-tetrahydrofolic acid, 5,10-methylene-(6R,S)-tetrahydrofolate, 5,10-methylene-(6R)-tetrahydrofolate, 5-methyl-(6R,S)-tetrahydrofolate or 5-methyl-(6S)-tetrahydrofolate and one or more of the compounds sodium gluconate, potassium gluconate, glycerophosphate disodium salt or glycerophosphate dipotassium salt. | 2016-03-17 |
20160074403 | NOVEL IMMUNE SYSTEM MODULATORS - The present invention relates to a compound of Formula I: | 2016-03-17 |
20160074404 | ADMINISTRATION OF NEDD8-ACTIVATING ENZYME INHIBITOR AND CHEMOTHERAPEUTIC AGENTS - Disclosed are methods for the treatment of various solid tumors in patients in need of such treatment. The methods comprise administering to such a patient an NEDD8-activating enzyme (NAE) inhibitor such as (1S,2S,4R)-4-4-(1S)-2,3-dihydro 1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate (MLN4924) or a pharmaceutically acceptable salt in combination with one or more chemotherapeutic agents. Also disclosed are medicaments for use in the treatment of various solid tumors. | 2016-03-17 |
20160074405 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DRUG-INDUCED HAND-FOOT SYNDROME - The present invention provides methods of treating, ameliorating or preventing hand-foot syndrome in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a phosphodiesterase inhibitor. | 2016-03-17 |
20160074406 | DRY BLEND FORMULATION OF TETRAHYDROBIOPTERIN - Dry blend powder formulations comprising a pharmaceutical formulation containing tetrahydrobiopterin, and methods of making and using the same, are disclosed herein. | 2016-03-17 |
20160074407 | TRANSVAGINAL PHOSPHODIESTERASE INHIBITORS FOR INFERTILITY TREATMENT - The present invention relates to a new application of phosphodiesterase inhibitors for couple infertility treatment which forms an effective alternative to the invasive assisted reproductive techniques such as conjugal artificial insemination and which consists of the transvaginal administration of a phosphodiesterase inhibitor immediately before and/or after coitus. It also relates to dosage forms suitable for the intravaginal administration of phosphodiesterase inhibitors. | 2016-03-17 |
20160074408 | NOVEL COMPOSITIONS USEFUL IN TREATING BRAIN-RELATED DISEASES OR DISORDERS AND METHODS USING SAME - The present invention provides compounds useful for treating or preventing a brain-related disease or disorder. The present invention further provides a method of treating or preventing a brain-related disease or disorder in a patient, the method comprising administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of modulating the activity of a monoamine transporter. | 2016-03-17 |
20160074409 | Treatment of Skeletal-Related Disorders - The invention relates to the prevention and/or treatment of skeletal related disorders using heteroaryl compounds. | 2016-03-17 |
20160074410 | Beta2-ADRENOCEPTOR AGONIST FOR THE TREATMENT OF COUGH - This invention relates to the β2-adrenoceptor agonist Olodaterol or a pharmaceutically acceptable salt thereof, | 2016-03-17 |
20160074411 | USE OF LANDIOLOL HYDROCHLORIDE IN THE LONG-TERM TREATMENT OF TACHYARRHYTHMIAS - The invention provides a new use of landiolol hydrochloride for persistent reduction of the heart rate during the administration period of landiolol hydrochloride in the treatment of a human suffering from tachycardia, tachyarrhythmia or elevated blood pressure, wherein landiolol hydrochloride is administered at a constant dose of more than 5 μg/kg/min, specifically of at least 10 μg/kg/min for a period of at least 2 hours and wherein the heart rate and/or blood pressure of said patient are persistently reduced during the administration period compared to the heart rate and/or blood pressure before treatment and no overshooting effect occurs after termination of said administration. | 2016-03-17 |
20160074412 | Chemical Compounds - There is provided pyrimidinyl compounds of Formula (I), | 2016-03-17 |
20160074413 | SUBSTITUTED DIKETOPIPERAZINES AND THEIR USE AS OXYTOCIN ANTAGONISTS - Compounds of formula (1) | 2016-03-17 |
20160074414 | METHODS AND COMPOSITIONS FOR IBOGAINE TREATMENT OF IMPULSE CONTROL DISORDER, ANXIETY-RELATED DISORDERS, VIOLENCE AND/OR ANGER, OR REGULATING FOOD INTAKE - This invention provides a method for treating anxiety-related disorder or impulse control disorder, regulating food intake, attenuating food cravings, or treating anger and/or violence and disorders associated therewith in a patient, comprising administering to the patient in need thereof a therapeutically effective amount of ibogaine, ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof. | 2016-03-17 |
20160074415 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT - The invention relates to methods for preventing, slowing the progression of, delaying or treating metabolic disorders induced in patients by the treatment with neuroleptic agents comprising administering to the patients an SGLT2 inhibitor. | 2016-03-17 |
20160074416 | HIGH-STRENGTH TESTOSTERONE UNDECANOATE COMPOSITIONS - The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone C | 2016-03-17 |
20160074417 | SR-BI AS A PREDICTOR OF HUMAN FEMALE INFERTILITY AND RESPONSIVENESS TO TREATMENT - Methods of diagnosis and treatment of diseases and disorders related to de novo synthesis of cholesterol, based on allelic variants of the scavenger receptor class B type I receptor, and kits for use therein. | 2016-03-17 |
20160074418 | OCULAR IMPLANT MADE BY A DOUBLE EXTRUSION PROCES - The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release. | 2016-03-17 |
20160074419 | Preparation and Uses of Obeticholic Acid - The present invention relates to obeticholic acid: | 2016-03-17 |
20160074420 | ORAL B12 THERAPY - Methods of normalizing vitamin B | 2016-03-17 |
20160074421 | METHOD FOR THE TREATMENT OF DISEASES CAUSED BY HAEMORRHAGIC VIRUSES AND COMPOUNDS FOR USE IN SAID TREATMENT - Diseases caused by haemorrhagic viruses, such as the Ebola and Marburg viruses, can be treated by the administration of compounds comprising a high density negatively charged domain of vicinally oriented radicals. A method of treatment, a pharmaceutical composition, and a nutritional composition are disclosed. | 2016-03-17 |
20160074422 | MUCUS STRENGTHENING FORMULATIONS TO ALTER MUCUS BARRIER PROPERTIES - The present technology relates to compositions and methods that strengthen mucus barriers, e.g., reduce the permeability of the mucus barriers. In some embodiments, the compositions include a model bile and a lipid mixture, wherein the model bile includes at least one salt and a lecithin. In some embodiments, the composition is useful to treat necrotizing enterocolitis. | 2016-03-17 |
20160074423 | METHOD OF ATTENUATING REACTIONS TO SKIN IRRITANTS - The present invention is directed to a method of inhibiting CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Compositions of the invention are useful for the attenuation of CD1d-restricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g., contact hypersensitivity), for systemic administration to attenuate ongoing immune responses, and to provide hypoallergenic cosmetic products including pharmaceutical, cosmetic, and skin care compositions. Preferably, these compositions are in a form intended for topical administration. | 2016-03-17 |
20160074424 | Compositions for Use in Restoring Muscle Glycogen and/or Muscle Mass - The present invention relates to compositions comprising a steviol glycoside for use in restoring muscle glycogen by increasing the rate of glycogen re-synthesis in muscles that are depleted in glycogen due to exhaustive exercise and/or for use in treatment of muscle mass by increasing the rate of protein synthesis in muscles that are depleted in protein mass. | 2016-03-17 |
20160074425 | AMINOGLYCOSIDES AND USES THEREOF IN TREATING GENETIC DISORDERS - A new class of pseudo-trisaccharide aminoglycosides having an alkyl group at the 5″ position, exhibiting efficient stop codon mutation readthrough activity, low cytotoxicity and high selectivity towards eukaryotic translation systems are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders, as well as processes of preparing these aminoglycosides. The disclosed aminoglycosides can be represented by the general formula I: | 2016-03-17 |
20160074426 | AQUEOUS OPHTHALMIC FORMULATIONS BASED ON AZITHROMYCIN - The invention concerns topical ophthalmic preparations in the form of eye-drops in aqueous solution, containing azithromycin (or a pharmacologically acceptable salt thereof) as active ingredient, wherein the azithromycin is solubilized and stabilized by means of β-cyclodextrins, and in particular by means of the β-cyclodextrin called sulfobutyl ether β-cyclodextrin (SBE-β-CD). | 2016-03-17 |
20160074427 | METHODS AND COMPOSITIONS FOR ATTENUATING GENE EXPRESSION MODULATING ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES - Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants. | 2016-03-17 |
20160074428 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION - In accordance with the present invention, a method for inhibiting HIV infection and/or latency in a patient in need thereof is provided. An exemplary method entails administration of an effective amount of an agent which inhibits CD163 receptor activity in a target cells, wherein inhibition of CD163 activity is effective to impede HIV uptake into target monocytes. In another aspect of the invention, a screening method for identifying agents useful for the treatment of HIV infection is disclosed. An exemplary method entails incubating a population of monocytes expressing CD163 in the presence and absence of said test agent, b) contacting said monocytes with a compound that detectably labels said CD163, thereby determining CD163 expression levels in the presence or absence of said agent, agents which inhibit expression of CD163 in treated cells relative to untreated cells being useful for inhibiting HIV infection in said cell. | 2016-03-17 |
20160074429 | Low-Molecular-Weight Biotechnological Chondroitin 6-Sulphate for Prevention of Osteoarthritis - Disclosed is a low-molecular-weight (1000-5000 daltons) chondroitin sulphate (CS) produced by chemical sulphation and subsequent depolymerisation of a non-sulphated chondroitin backbone obtained with biotechnology techniques. The CS described is substantially monosulphated, mainly at the 6-position, with very little sulphation at the 4-position, and with a mono/disulphated disaccharide ratio and charge density similar to those of natural CS. Said biotechnological chondroitin 6-sulphate (C6S) is useful in the treatment and prevention of osteoarthritis and in acute and chronic inflammatory processes. | 2016-03-17 |
20160074430 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION - Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human. | 2016-03-17 |
20160074431 | Methods and Compositions for Improving Appearance and Formation of Scar Tissue - This invention relates to methods and compositions for degrading collagen in mammalian skin, thereby improving the appearance and/or reducing the size of a closed wound, which may be a scar or a keloid and cellulite or other conditions wherein excessive collagen is a problem. | 2016-03-17 |
20160074432 | METHOD OF TREATING SINUSITIS, INCLUDING CHRONIC SINUSITIS - The present invention relates to a method for treating acute and chronic sinusitis, and in particular, severe chronic sinusitis by exposing affected tissue of the sinus and contiguous tissue in the, nasal cavity and greater oral cavity to effective amounts of chlorine dioxide as a bioactive agent. Compositions and methods of treatment are disclosed herein. | 2016-03-17 |
20160074433 | TREATING AGENT AND TREATING METHOD FOR THE EXAMINATION OR OPERATION OF THE LARGE INTESTINE - A treating agent for the examination or operation of the large intestine which has high examination precision or facilitates an operation and can be administered with a small amount of water. The treating agent for the examination or operation of the large intestine contains magnesium oxide particles and is used to be orally administered before an examination or operation. | 2016-03-17 |
20160074434 | Application Device for Inducing Cytotoxicity to Tumor Cells Via Coated Cerium Oxide Nanoparticles - Differential surface-charge-dependent localization of nanoceria in normal cells and cancer cells plays a critical role in the toxicity profile of a nanoceria particle. Engineered surface-coated cerium oxide nanoparticles with different surface charges that are positive, negative and neutral provide therapeutic results for normal and cancer cell lines. Results show that nanoceria with a positive or neutral charge enters most of the cell lines studied, while nanoceria with a negative charge internalizes mostly in the cancer cell lines. Moreover, upon entry into the cells, nanoceria is localized to different cell compartments (e.g. cytoplasm and lysosomes) depending on the nanoparticle surface charge. The internalization and subcellular localization of nanoceria plays a key role in the nanoparticle cytotoxicity profile, exhibiting significant toxicity when they localize in the lysosomes of the cancer cell lines. In contrast, minimal toxicity is observed when they localize into the cytoplasm or do not enter the cells. | 2016-03-17 |
20160074435 | KILLING ANTIBIOTIC-RESISTANT BACTERIA WITH A FORMULATION THAT IS SAFE FOR ORAL ADMINISTRATION - The teachings provided herein generally relate to binding systems that kill antibiotic-resistant bacteria, wherein the binding systems are safe for oral administration. More particularly, the systems taught herein include methods of treating a subject having an antibiotic-resistant bacterial infection, comprising administering an effective amount of a binding system to a subject having an antibiotic-resistant bacterial infection. The binding system can be administered orally in a formulation having, for example, a tannin having a gallic acid ester and hydrogen peroxide in a pharmaceutically acceptable carrier. | 2016-03-17 |
20160074436 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THEIR PRODUCTION - This invention relates to a method for preparing compositions for preventing or treating microbial infections, compositions suitable for use in such treatments and methods for treatment or prevention of infections. One such composition finds particular use in treating mastitis in ruminants. The composition is administered into the udder of an animal as a highly effective treatment for mastitis, or as a prophylactic therapy, by means of an intra-mammary infusion. The milk produced by the animal, during treatment using the composition and method of the invention, is free of residues, such as antibiotics, antimicrobial agents or antimicrobial proteins, which could affect its suitability for drinking or in the production of milk products, such as cheese or yoghurt. The compositions and methods are also useful in treating and preventing lung infections; and infections in burns and wounds; and other infections caused by biofilms. The compositions may also be used on medical devices to prevent infection. | 2016-03-17 |
20160074437 | IMMUNOLOGICAL TREATMENT OF LIVER FAILURE - Disclosed are means of treatment of liver failure and augmentation of liver regeneration by utilization of immune modulation through administration of immunocytes and mesenchymal stem cells. In one embodiment liver failure is treated by cord blood mononuclear cells administered allogeneic to the host that have been pretreated with hepatogenic cytokines. | 2016-03-17 |
20160074438 | PHARMACEUTICAL COMPOSITIONS FOR TREATING DEGENERATIVE NEUROLOGICAL DISEASE WITH MITOCELLS - A MitoCells treated with angelica extract is provided. The pharmaceutical composition comprise MitoCells and can significantly achieve the goal for treating degenerative neurological disease. | 2016-03-17 |
20160074439 | TREATMENT OF PAIN USING PLACENTAL STEM CELLS - Provided herein are methods of treatment of an individual having pain, e.g., neuropathic pain, comprising administering to the individual a therapeutically effective amount of tissue culture plastic adherent placental stem cells (PDAC™). | 2016-03-17 |
20160074440 | USE OF MICROORGANISMS FOR REDUCING THE LEVEL OF TRIMETHYLAMINE IN A HUMAN BODY CAVITY, IN PARTICULAR FOR THE TREATMENT OF TRIMETHYLAMINURIA OR OF BACTERIAL VAGINOSIS AND THE PREVENTION OF CARDIOVASCULAR DISEASES - Composition containing a microorganism, preferably an Archaea, expressing a TMA methyltransferase and a TMA methyl group acceptor corrinoid protein, capable of metabolizing trimethylamine (TMA) in the presence of hydrogen in a human cavity, such as the intestine or the vagina, for use as a medicament for treating, reducing or eliminating TMA at the level of the human cavity. In addition, a composition containing a TMA methyltransferase and a TMA methyl group acceptor corrinoid protein. These compositions are of use for treating trimethylaminuria, for treating vaginal fluids in the case of bacterial vaginosis and for reducing or eliminating odours due to TMA. These compositions are also of use for reducing the level of plasma TMAO, for preventing the formation of atheroma plaques and/or for preventing cardiovascular diseases. | 2016-03-17 |
20160074441 | SALMONELLA STRAINS FOR USE IN THE TREATMENT AND/OR PREVENTION OF CANCER - The present invention relates to a pharmaceutical composition comprising a live attenuated non-recombinant mutant of | 2016-03-17 |
20160074442 | Method of making a medication or a food supplement - The invention relates to a pharmaceutical and/or dietetic composition for increasing the impact of the immune defense of higher living beings, wherein bacteria of the species | 2016-03-17 |
20160074443 | NANO-SIZED KIMCHI LACTIC ACID BACTERIA - Provided is nano-sized kimchi lactic acid bacteria, and more particularly, to | 2016-03-17 |
20160074444 | LACTOBACILLUS RHAMNOSUS STRAIN FOR REGULATING LIPID METABOLISM - The invention relates to the use of a strain of | 2016-03-17 |
20160074445 | COMPOSITIONS AND METHODS FOR REDUCING BLOOD ALCOHOL CONTENT - Disclosed are compositions and methods for reducing blood alcohol content following alcohol consumption. The inventive compositions and methods rapidly reduce blood alcohol content and alleviate symptoms of intoxication in a subject having an elevated blood alcohol content due to alcohol consumption. | 2016-03-17 |
20160074446 | Antibacterial Phage, Phage Peptides And Methods Of Use Thereof - The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophage F387/08, F391/08, F394/08, F488/08, F510/08, F44/10, and F125/10, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophage and/or isolated polypeptides, as well as to methods for the treatment and prevention of bacterial infections using same, either alone or in combination with other antibacterial therapies, e.g., antibiotics and/or other phage therapies. | 2016-03-17 |
20160074447 | NOVEL USE OF ADENOVIRUSES AND NUCLEIC ACIDS THAT CODE FOR SAID VIRUSES - The present invention is related to the use of a virus, preferably an adenovirus, for the manufacture of a medicament, whereby the virus is replication deficient in cells which do not have YB-1 in the nucleus, and the virus codes for an oncogene or oncogene product, in particular an oncogene protein, which transactivates at least one viral gene, preferably an adenoviral gene, whereby the gene is selected from the group comprising E1B55kDa, E4orf6, E4orf3 and E3ADP. | 2016-03-17 |
20160074448 | HERPES SIMPLEX VIRUS (HSV) WITH MODIFIED TROPISM, USES AND PROCESS OF PREPARATION THEREOF - A modified Herpes Simplex Virus (HSV), which has a portion of gD (glycoprotein D) of the glycoproteic envelope deleted and a heterologous single chain antibody inserted in place of such deleted portion; the modified HSV is capable of infecting cells through receptor HER2/ErbB2 but not through receptors HVEM/HveA and nectin1/HveC; uses of the modified HSV and a process of the preparation thereof are also disclosed. | 2016-03-17 |
20160074449 | Food Composition for Increased Breast Milk Production - A baked good that promotes the production of breast milk in a nursing mother. The present food composition is intended to increase the production of milk while being presented in a baked form. It is prepared with brewer's yeast, vanilla extract, and water. The composition is further intended to be prepared by means of baking the ingredients in an oven, so that the final food composition is in a solid form. There are several embodiments of the present invention, including in a cookie, muffin, and brownie form. | 2016-03-17 |
20160074450 | Essential Element Management - The invention extends the utility of apparatus used to extract medicinal cannabis compounds into an eluate by separating a portion of medicinal cannabis compounds contained within a portion of eluate at a first extraction target level providing enough clean solvent to continue extraction operations. A high efficiency concentrator such as a rotary evaporator or a wiped film evaporator processes eluate from one or more tanks or extraction vessels creating clean solvent when extraction targets are met or when clean solvent is exhausted. This manages eluate concentration levels and limits the quantity of concentrated medicinal cannabis compounds on site at any moment in time. The invention enables a business model for keeping medicinal cannabis compounds within a legal system, and reduces pollution because law enforcement would no longer have to burn large quantities of cannabis plant matter. | 2016-03-17 |
20160074451 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING - The present invention provides for methods of obtaining an extract of | 2016-03-17 |
20160074452 | CHROMIUM-CONTAINING COMPOSITIONS IN COMBINATION WITH PHYLLANTHUS EMBLICA AND SHILAJIT HAVING SYNERGISTIC EFFECTS FOR IMPROVING ENDOTHELIAL FUNCTION AND CARDIOVASCULAR HEALTH - Chromium-three cation containing compositions in synergistic combination with | 2016-03-17 |
20160074453 | A METHOD AND COMPOSITION USING MYRRH, DILL AND PEEL OF POMEGRANATE AS A NATURAL REMEDY FOR CHRONIC WOUNDS - A method of making a homogenized powder comprising | 2016-03-17 |
20160074454 | PHARMACEUTICAL COMPOSITION BASED ON CENTELLA ASIATICA (HYDROCOTYLE ASIATICA L.) FOR THE TREATMENT OF LOWER LIMB ULCERS - A pharmaceutical composition based on | 2016-03-17 |
20160074455 | Active ingredient obtained from calendula officinalis and use in the prevention and treatment of cutaneous manifestations due to an imbalance in the epigenome in skin cells - The use of an active ingredient obtained from | 2016-03-17 |
20160074456 | XANTHOPHYLL COMPOSITIONS AND METHODS OF USE - The present invention encompasses a carotenoid composition, a process for producing a carotenoid composition, and methods of use thereof. | 2016-03-17 |
20160074457 | COMPOSITION FROM SPHAERANTHUS INDICUS AND GARCINIA MANGOSTANA FOR THE CONTROL OF METABOLIC SYNDROME - Pharmaceutical/dietary supplements and food ingredient(s) derived from | 2016-03-17 |
20160074458 | COMPOSITION FOR PREVENTION AND TREATMENT OF MILIARIA - A composition for prevention and treatment of miliaria is disclosed by use of a purslane extract with or without a | 2016-03-17 |
20160074459 | PLANT EXTRACTS FOR IMPROVING COGNITIVE FUNCTION - Extracts of plants of the Lamiaceae family, including the | 2016-03-17 |
20160074460 | PLANT EXTRACTIONS, COMPOSITIONS CONTAINING SAME, AND USES THEREOF - This disclosure relates to plant extracts selected from | 2016-03-17 |
20160074461 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT - The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the α | 2016-03-17 |
20160074462 | Method of Treating HCV - This application features methods of treating HCV using Compound 1/r, Compound 2 and/or Compound 3. | 2016-03-17 |
20160074463 | USE OF THE PAT NONAPEPTIDE IN THE TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES - A PAT nonapeptide of formula EAKSQGGSD can be used to treat or prevent neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Pharmaceutical compositions containing the PAT nonapeptide can be formulated for administration by parenteral route, including the subcutaneous, intraperitoneal, intravenous or intranasal routes. | 2016-03-17 |
20160074464 | ANGIOTENSINS IN MUSCULAR DYSTROPHY - The present invention provides, among other things, methods of treating a muscular dystrophy including administering to a subject suffering from or susceptible to a muscular dystrophy an angiotensin (1-7) peptide. | 2016-03-17 |
20160074465 | Methods for Treating Hypotension - The present disclosure relates to the use of angiotensin II in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension. | 2016-03-17 |
20160074466 | ANGIOTENSINS FOR TREATMENT OF FIBROSIS - The present invention provides, among other things, methods and compositions for treating or preventing fibrotic diseases, disorders or conditions based on Angiotensin (1-7) polypeptides, and analogs or derivatives thereof. In some embodiments, compositions and methods for treating or preventing pulmonary fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, kidney fibrosis, liver fibrosis, systemic sclerosis, post-surgical adhesions, accelerating wound healing, and reducing or preventing scar formation are provided. | 2016-03-17 |
20160074467 | TREATMENT OF AGING EFFECTS BY GONADOTROPIN-RELEASING HORMONE, NEUROGENESIS OR BRAIN IKK BETA/NF-KAPPAB INHIBITION - Methods are disclosed for treating effects of aging using gonadotropin-releasing hormone, agents that inhibit IκB kinase-β (IKK-β) and/or nuclear factor κB (NF-κB), and/or agents that promote neurogenesis. | 2016-03-17 |
20160074468 | COMBINATION ANTI-HER2 CANCER THERAPY USING MUC1 PEPTIDES AND CHEMOTHERAPEUTICS - The invention provides for treatment of HER2+ cancers using a combination of anti-MUC1 therapy and anti-HER2 therapy. In particular, the invention addresses the treatment of trastuzamab-resistant cancers, both primary and acquired, using the same combination of agents. | 2016-03-17 |
20160074469 | ALPHA-AND GAMMA-MSH ANALOGUES - The present invention provides peptide analogues of α-MSH and γ-MSH, comprising the amino acid sequence of human α-MSH or γ-MSH, or variants thereof, and having a branched amino acid probe in the N-terminal part of the peptide. | 2016-03-17 |
20160074470 | METHOD FOR PROMOTING HAIR GROWTH - The present disclosure relates to a method of applying a pharmaceutical composition for promoting hair growth. The pharmaceutical composition includes a hair growth peptide (HGP) which includes all or part of the amino acid sequence SEQ ID No: 1. The method includes administering a hair growth peptide (HGP) which includes all or part of the amino acid sequence SEQ ID No: 1 to a party of interest. | 2016-03-17 |
20160074471 | USE OF HUMAN SMALL LEUCINE ZIPPER PROTEIN IN ADIPOCYTE DIFFERENTIATION PROCEDURE - The present invention relates to a use of a human small leucine zipper protein in the adipocyte differentiation procedure. More specifically, sLZIP binds with PPARγ2 to induce the formation of a complex of HDAC3 and PPARγ2, thereby functioning as a corepressor to negatively inhibit the transcriptional activity of PPARγ2 and suppress the differentiation to adipocytes, and thus can be used as a marker for treating diabetes and obesity and developing new medicines therefor. | 2016-03-17 |
20160074472 | Inhibitors of Phosphatase and Tensin Homolog (PTEN) Compositions, Uses and Methods - Described herein are isolated polypeptides having phosphatase and tensin homolog (PTEN) inhibitory activity, vectors and cells for the expression thereof and methods for their use in treating diseases associated with cytotoxic stress, such as spinal cord injury, stroke, traumatic brain injury, multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Huntington's disease. | 2016-03-17 |
20160074473 | EFFECT OF PHOSPHOLIPID COMPOSITION OF RECONSTITUTED HDL ON ITS CHOLESTEROL EFFLUX AND ANTI-INFLAMMATORY PROPERTIES - The present invention relates to peptide-phospholipid formulations, methods of generating these formulations and methods of administering these formulations for treatment. The present disclosure also provides methods for increasing cholesterol efflux, inducing anti-atherosclerotic activity, increasing pre-β HDL, inducing anti-inflammatory activity, inhibiting cytokine release (including cytokines TNF-α, IL-1β, and/or IL-6 or a combination thereof) and increasing cholesterol mobilization and/or esterification by administering the peptide-phospholipid formulations disclosed. | 2016-03-17 |
20160074474 | COMPOSITIONS AND METHODS FOR TREATING SPINAL MUSCULAR ATROPHY - The present provides methods for treating spinal muscular atrophy using a self-complementary recombinant adeno-associated virus (rAAV) viral particle comprising a transgene expressing SMN. In one aspect, the viral particles are administered the spinal column or cisterna magna in a human subject; for example, a pediatric human subject. Viral particles comprising AAV9 capsids are contemplated. | 2016-03-17 |
20160074475 | CONJUGATES FOR THE ADMINISTRATION OF BIOLOGICALLY ACTIVE COMPOUNDS - The invention relates to a conjugate that comprises an Apo A molecule or a functionally equivalent variant thereof and a compound of therapeutic interest wherein both components are covalently coupled as well as to the use of said conjugates in therapy for the specific targeting of said compounds to those tissues showing specific binding sites for the Apo A molecule. | 2016-03-17 |
20160074476 | Modulation of Heparin-binding Epidermal Growth Factor Activity for Tympanic Membrane Healing - Compositions and methods are provided for the generation or treatment of chronic tympanic membrane perforation by modulation of HB-EGF activity. | 2016-03-17 |
20160074477 | METHODS AND COMPOSITIONS FOR REJUVENATING SKELETAL MUSCLE STEM CELLS - Methods and compositions for rejuvenating skeletal muscle stem cells are disclosed. | 2016-03-17 |
20160074478 | Novel Target for Diagnosis and Treatment of Diabetes and Cardiovascular Diseases - Diagnostic, prognostic, and treatment methods, compositions, and kits for enhancing insulin secretion and beta cell numbers and functions, and controlling glycemia associated with diabetes, obesity, atherosclerosis, stroke, myocardial infarction, and other cardiovascular diseases, by modulating FKN/CX3CR1 expression levels or activities, and its downstream signaling pathways in a subject in need or at risk. | 2016-03-17 |
20160074479 | METHODS OF TREATING SPINAL DISORDERS USING AUTOLOGOUS PROTEIN SOLUTIONS - Methods for treating a spinal disorder, such as spinal pain or spinal inflammation, using a blood-derived composition having two or more of IL1-ra, sTNF-R1, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-β1, and sIL-1RII. Compositions may also contain white blood cells and platelets. | 2016-03-17 |
20160074480 | INNOVATIVE METHODS OF TREATMENTING TUBERCULOSIS - A Safe and effective treatment methods to cure and curtail tuberculosis affliction described using high dose Vitamin C, and other known anti- | 2016-03-17 |
20160074481 | Clottable Concentrate Of Platelet Growth Factors And Preparation Method Thereof - The present disclosure relates to a clottable concentrate of platelet growth factors for therapeutic and/or cosmetic use, preferably comprising the growth factors PDGF, TGT-β, IGF, EGF, CTGF, bFGF and VEGF. In a preferred embodiment, the clottable concentrate of platelet growth factors does not induce blood cell-related transfusion reactions. The present disclosure also relates to a method for preparing a clottable concentrate of platelet growth factors including the steps of contacting a platelet concentrate with a solvent and/or a detergent, incubating the platelet concentrate with the solvent and/or detergent for a period of at least 5 minutes to 6 hours, at a pH maintained in a range from about 6.0 to about 9.0, and at a temperature within the range of from 2° C. to 50° C., preferably within the range of from 25° C. to 45° C., and removing the solvent and/or the detergent by oil extraction and/or chromatographic means. | 2016-03-17 |
20160074482 | Compositions and Methods for Producing Vascular Occlusion using a Solid-phase Platelet Binding Agent - The present invention relates generally to methods and compositions for targeting and delivering solid-phase platelet-dependent vascular occlusion agents. In particular, particles or coils or stents coated with platelet binding agents are directed to target vasculature, such as the vasculature of solid tumor masses or AV-malformations or aneurysms or endoleaks; the solid-phase agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the rapid formation of a platelet-mediated thrombus about the solid-phase agent causing vessel occlusion. | 2016-03-17 |